semaglutide ruling fda compounded is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market FDA is cracking down on – US FDA to hold off

Muscle & Tissue Signaling Research: Examining cellular responses related to structural protein signaling, repair coordination, and growth-factor pathway activation

Starting in 2026, Medicare will begin covering select GLP-1 medications for obesity under a new policy that expands access to these medications

Symptoms to watch for: persistent fatigue despite adequate sleep, cold intolerance, hair thinning (especially the outer third of the eyebrows), constipation, brain fog, weight that won't budge despite tight nutrition, dry skin, low resting heart rate

Patients in this situation should be advised to adopt a non-hormonal form of birth control

however, the trial duration (24 weeks) and sample size were insufficient to detect or exclude rare adverse events